Future Market Insights (FMI), a leading provider of market intelligence and consulting services, today released its comprehensive analysis of the Demand for artificial pancreas device systems in Japan is projected to grow from USD 17.4 million in 2025 to USD 32.8 million by 2035, reflecting a compound annual growth rate (CAGR) of 6.5%. Growth is driven by the increasing prevalence of diabetes in Japan, particularly type 1 diabetes, and the growing demand for advanced systems that help manage blood glucose levels. Artificial pancreas devices, which combine an insulin pump with continuous glucose monitoring (CGM) to automate insulin delivery, are transforming the way diabetes is managed, improving patient quality of life and outcomes. As more patients with type 1 and type 2 diabetes seek better management solutions, the adoption of artificial pancreas systems is expected to rise steadily. This growth trajectory underscores Japan’s position as a leader in adopting advanced diabetes management technologies, driven by its robust healthcare infrastructure, aging population, and commitment to improving patient outcomes for those living with diabetes.
Artificial pancreas device systems represent a transformative leap in diabetes care. By integrating continuous glucose monitoring (CGM) with automated insulin delivery, these systems mimic the function of a healthy pancreas, reducing the daily burden of manual glucose management and minimizing risks of hypoglycemia and hyperglycemia. For patients, particularly those with type 1 diabetes, APDS offer greater freedom, better glycemic control, and enhanced quality of life.
The FMI report highlights that threshold suspend device systems will continue to dominate the market, commanding approximately 72.5% to 73% share due to their proven reliability in preventing low blood sugar events by automatically suspending insulin delivery when glucose levels drop critically. Meanwhile, the type 1 diabetes indication segment leads with a 56.3% market share, reflecting the acute need for automated solutions among patients requiring lifelong insulin therapy.
Japan’s market dynamics are shaped by several compelling factors. The country faces a rising incidence of diabetes, exacerbated by an aging population—one of the world’s oldest—with increasing cases of both type 1 and type 2 diabetes. This demographic shift, combined with growing awareness of diabetes-related complications, is fueling demand for innovative tools that not only manage blood glucose but also reduce long-term healthcare costs.
Technological advancements play a pivotal role. Improvements in sensor accuracy, insulin pump efficiency, and hybrid closed-loop systems are accelerating adoption. Patients and healthcare providers increasingly favor automated insulin delivery over traditional manual methods, with CGM integration becoming a standard expectation. Japan’s strong emphasis on medical device innovation, supported by government initiatives to enhance diabetes care access, further propels this shift toward personalized, tech-enabled solutions.
Regionally, growth is uneven but promising. Kyushu & Okinawa lead with the highest projected CAGR of 8.2%, followed by Kanto at 7.5% and Kansai at 6.6%. These variations highlight opportunities for targeted expansion in high-growth areas, where diabetes prevalence and healthcare infrastructure align favorably.
Leading the competitive landscape are global innovators such as Medtronic, a frontrunner in integrated APDS; Insulet Corporation, known for tubeless pump technologies; Tandem Diabetes Care, Inc., advancing algorithm-driven systems; Abbott Laboratories, with strong CGM offerings; and Beta Bionics, pushing boundaries in bi-hormonal approaches. These companies are investing in regulatory approvals tailored to Japan, device usability enhancements, and partnerships to broaden access.
Despite the optimistic outlook, challenges remain. High device costs can limit affordability, particularly for patients without comprehensive insurance coverage. Complexity in usage requires specialized training, and regional disparities in healthcare access—especially in rural areas—pose barriers. Long-term concerns around system reliability and component integration also warrant ongoing research.
However, these restraints are outweighed by substantial opportunities. Advances in remote monitoring, digital health integration, and personalized medicine are opening new avenues. Broader application in homecare settings, specialty clinics, and even acute care scenarios signals untapped potential. As regulatory support strengthens and costs potentially decline with scale, APDS adoption is expected to accelerate.
Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates: https://www.futuremarketinsights.com/reports/brochure/rep-gb-29735
Request for Discount: https://www.futuremarketinsights.com/reports/sample/rep-gb-29735
Industry leaders view Japan’s APDS market as a benchmark for precision healthcare. “This steady growth reflects not just demographic necessities but Japan’s proactive embrace of technology to empower patients,” notes an FMI analyst. “Decision-makers in medtech should prioritize investments here—focusing on user-centric design, affordability strategies, and localized innovations—to capture share in a market poised for sustained leadership in diabetes management.”
The FMI report provides decision-grade insights for stakeholders, including year-by-year forecasts (e.g., USD 18.6 million in 2026, USD 19.8 million in 2027, rising steadily to USD 32.8 million by 2035), segmental breakdowns, and competitive analyses. As Japan continues to pioneer advanced diabetes solutions, the artificial pancreas device system market stands as a testament to how innovation can profoundly impact public health.
About Future Market Insights (FMI)
Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.
Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us – [email protected]



